Real-world glucocorticoid prescription patterns in patients with lupus nephritis: A retrospective study using a healthcare insurance claims database.

ABSTRACT: ObjectiveWhile oral glucocorticoids (GC) have improved the prognosis of lupus nephritis (LN), dose reduction to ≤5.0 mg/day is recommended, considering their toxicity. We investigated the real-world prescription status following dose reduction of oral GC after starting initial therapy in patients with LN.MethodsData were extracted from the JMDC insurance claims database between May 2016 and March 2023 with the following inclusion criteria: patients with ≥2 LN diagnoses; follow-up for ≥90 days pre-index and ≥540 days post-index; oral GC dose ≥20.0 mg/day (prednisolone equivalent) or intravenous glucocorticoid pulse; ≥2 urinalyses, anti-double stranded DNA antibody, and complement tests within 360 days post-index. Descriptive analyses were performed by characterization as dose reduction targ

SUBMITTER: Atsumi T 

PROVIDER: S-EPMC12830505 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature